A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in Europe, Canada, and Asia.
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 01 Sep 2012 Actual end date (24 May 2012) added as reported by European Clinical Trials Database.
- 23 Jun 2012 Additional location (Canada) added as reported by European Clinical Trials Database record.
- 24 May 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.